BACKGROUND: As the methodologies for evaluating health-related quality of life (HRQOL) in head and neck cancer patients have matured over the past 10 years, there has been an increasing focus on reporting longitudinal data. These studies have primarily focused on long-term survivors. This study addresses the HRQOL of both long-term and short-term survivors. METHODS: This is a prospective, longitudinal study of 479 head and neck cancer patients followed for at least 3 years after diagnosis. Analysis of longitudinally collected HRQOL scores was based on survivorship status. RESULTS: The HRQOL for 3 survivorship groups: short-term (died <1 year), intermediate-term (died 1-3 years), and long-term survivors (alive >3 years) were different at all time points (pretreatment, 3, 6, and 12 months). Differences were greatest between the short-term and long-term survivors. Long-term survivors demonstrated the best HRQOL and an improving HRQOL trajectory at 12 months. The HRQOL of short-term survivors declined precipitously throughout all available follow-up. Intermediate-term survivors did show some improvement following treatment but had a declining HRQOL trajectory at 12 months. CONCLUSION: The HRQOL profiles of head and neck cancer patients differed significantly depending on survivorship status. Long-term HRQOL results should be analyzed within the context of the results for all of the patients eligible to have been included in the initial study cohort.
BACKGROUND: As the methodologies for evaluating health-related quality of life (HRQOL) in head and neck cancerpatients have matured over the past 10 years, there has been an increasing focus on reporting longitudinal data. These studies have primarily focused on long-term survivors. This study addresses the HRQOL of both long-term and short-term survivors. METHODS: This is a prospective, longitudinal study of 479 head and neck cancerpatients followed for at least 3 years after diagnosis. Analysis of longitudinally collected HRQOL scores was based on survivorship status. RESULTS: The HRQOL for 3 survivorship groups: short-term (died <1 year), intermediate-term (died 1-3 years), and long-term survivors (alive >3 years) were different at all time points (pretreatment, 3, 6, and 12 months). Differences were greatest between the short-term and long-term survivors. Long-term survivors demonstrated the best HRQOL and an improving HRQOL trajectory at 12 months. The HRQOL of short-term survivors declined precipitously throughout all available follow-up. Intermediate-term survivors did show some improvement following treatment but had a declining HRQOL trajectory at 12 months. CONCLUSION: The HRQOL profiles of head and neck cancerpatients differed significantly depending on survivorship status. Long-term HRQOL results should be analyzed within the context of the results for all of the patients eligible to have been included in the initial study cohort.
Authors: Lorraine R Reitzel; Nga Nguyen; Mark E Zafereo; Guojun Li; Qingyi Wei; Erich M Sturgis Journal: Health Place Date: 2012-03-14 Impact factor: 4.078
Authors: Barbara A Head; Luke Heitz; Cynthia Keeney; John Myers; Savitri N Appana; Jamie L Studts; Jeffrey Bumpous; Mark Pfeifer Journal: Support Care Cancer Date: 2010-08-21 Impact factor: 3.603
Authors: Quynh-Nhu Nguyen; Stephen G Chun; Edward Chow; Ritsuko Komaki; Zhongxing Liao; Rensi Zacharia; Bill K Szeto; James W Welsh; Stephen M Hahn; C David Fuller; Bryan S Moon; Justin E Bird; Robert Satcher; Patrick P Lin; Melenda Jeter; Michael S O'Reilly; Valerae O Lewis Journal: JAMA Oncol Date: 2019-06-01 Impact factor: 31.777
Authors: Hsiao-Lan Wang; Juanita F Keck; Michael T Weaver; Alan Mikesky; Karen Bunnell; Janice M Buelow; Susan M Rawl Journal: Rehabil Res Pract Date: 2013-12-25
Authors: Annette J van Nieuwenhuizen; Laurien M Buffart; Jan H Smit; Ruud H Brakenhoff; Boudewijn J M Braakhuis; Remco de Bree; C René Leemans; Irma M Verdonck-de Leeuw Journal: Support Care Cancer Date: 2014-08-12 Impact factor: 3.603